Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?
Purpose of Review
Ever since the reprogramming of human fibroblasts to induced pluripotent stem cells (hiPSCs), scientists have been trying to determine if hiPSCs can give rise to progeny akin to native terminally differentiated cells as human embryonic stem cells (hESCs) do. Many different somatic cell types have been successfully reprogrammed via a variety of methods. In this review, we will discuss recent studies comparing hiPSCs and hESCs and their ability to differentiate to desired cell types as well as explore diabetes disease models.
Both somatic cell origin and the reprogramming method are important to the epigenetic state of the hiPSCs; however, genetic background contributes the most to differences seen between hiPSCs and hESCs.
Based on our review of the relevant literature, hiPSCs display differences compared to hESCs, including a higher propensity for specification toward particular cell types based on memory retained from the somatic cell of origin. Moreover, hiPSCs provide a unique opportunity for creating diabetes disease models.
KeywordsHuman pluripotent stem cells Diabetes Reprogramming Differentiation Disease models
Funding support has been provided by the National Science Foundation (NSF), award CBET-1743367.
Compliance with Ethical Standards
Conflict of Interest
Elena F. Jacobson and Emmanuel S. Tzanakakis declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 14.•• Choi J, Lee S, Mallard W, Clement K, Tagliazucchi GM, Lim H, et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol. 2015;33(11):1173–81 Study used isogenic hESCs and hiPSCs for comparison to determine the role of genetic background on epigenetic differences between hESCs and hiPSCs. CrossRefPubMedPubMedCentralGoogle Scholar
- 17.•• Thurner M, Shenhav L, Wesolowska-Andersen A, Bennett AJ, Barrett A, Gloyn AL, et al. Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells. Stem Cell Rep. 2017;9(5):1395–405 The open chromatin structure (associated with active gene transcription) of β cell-derived hiPSCs compared to fibroblast-originating hiPSCs as they relate to open chromatin structures in human islets was studied.CrossRefGoogle Scholar
- 20.•• Braverman-Gross C, Nudel N, Ronen D, Beer NL, McCarty MI, Benvenisty N. Derivation and molecular characterization of pancreatic differentiated MODY1-iPSCs. Stem Cell Res. 2018;31:16–26 hiPSCs were derived from a MODY1 (HNF4A transcription factor mutation) patient and differentiated to the pancreatic lineage. It was reported that the HNF4A target gene's differential expression depends on the number of HNF4A binding sites. The effect is more pronounced if the binding sites are closer to the target gene transcription start site and the target gene has fewer binding sites for other transcription factors in its promoter.CrossRefPubMedGoogle Scholar
- 21.• Teo AK, Lau HH, Valdez IA, Dirice E, Tjora E, Raeder H, et al. Early developmental perturbations in a human stem cell model of MODY5/HNF1B pancreatic hypoplasia. Stem Cell Rep. 2016;6(3):357–67 Human iPSCs were generated from a MODY5 (HFN1B mutation) patient and differentiated to pancreatic cell progenitors. The resulting cells show increased expression of several pancreatic cell transcription factors ( PDX1 , PTF1A , GATA4 , and GATA6 ) and a decrease in PAX6 expression in comparison to the control.CrossRefGoogle Scholar
- 23.• Vethe H, Bjorlykke Y, Ghila LM, Paulo JA, Scholz H, Gygi SP, et al. Probing the missing mature beta-cell proteomic landscape in differentiating patient iPSC-derived cells. Sci Rep. 2017;7(1):4780 Human iPSCs were produced from a MODY1 patient and successfully differentiated into insulin-positive cells. This suggests that a HNF4A mutation does not prevent expression of insulin genes. The differentiated cells were shown to be immature in comparison to human islets. CrossRefPubMedPubMedCentralGoogle Scholar
- 26.• Hosokawa Y, Toyoda T, Fukui K, Baden MY, Funato M, Kondo Y, et al. Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: vulnerability to cytokine insults and increased expression of apoptosis-related genes. J Diabetes Investig. 2017. https://doi.org/10.1111/jdi.12727. Human iPSCs were derived from a patient with fulminant type 1 diabetes to better understand β-cell destruction. Differences were observed vs. control hiPSCs in response to cytokines.
- 31.Griscelli F, Ezanno H, Soubeyrand M, Feraud O, Oudrhiri N, Bonnefond A, et al. Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 3 (MODY3) carrying a hepatocyte nuclear factor 1-alpha (HNF1A) mutation. Stem Cell Res. 2018;29:56–9.CrossRefPubMedGoogle Scholar